August 10, 2018 – By Jimmy Cauthen
Inflarx N.V. (NASDAQ:IFRX) had an increase of 20.41% in short interest. IFRX’s SI was 217,700 shares in August as released by FINRA. Its up 20.41% from 180,800 shares previously. With 72,600 avg volume, 3 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The stock decreased 0.44% or $0.135 during the last trading session, reaching $30.495. About 430 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since August 10, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa
AVROBIO, Inc. (AVRO) formed double top with $39.73 target or 4.00% above today’s $38.20 share price. AVROBIO, Inc. (AVRO) has $914.39 million valuation. The stock increased 0.37% or $0.14 during the last trading session, reaching $38.2. About 1,218 shares traded. AVROBIO, Inc. (NASDAQ:AVRO) has 0.00% since August 10, 2017 and is . It has underperformed by 12.57% the S&P500.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $782.57 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx NV Reports Second Quarter 2018 Financial & Operating Results” on August 09, 2018, also Schaeffersresearch.com with their article: “3 Healthcare Stocks Making Massive Moves” published on July 13, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on July 13, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Streetinsider.com and their article: “BMO Capital Starts Inflarx NV (IFRX) at Outperform” published on July 13, 2018 as well as Benzinga.com‘s news article titled: “30 Stocks Moving In Friday’s Mid-Day Session” with publication date: July 13, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.